Patents by Inventor Henning Thogersen

Henning Thogersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Peptides for Use in the Treatment of Obesity
    Publication number: 20090203581
    Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
    Type: Application
    Filed: July 7, 2006
    Publication date: August 13, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Ulrich Sensfuss, Leif Christensen, Jane Spetzler, Kilian Waldemar Conde Frieboes, Henning Thogersen
  • Glucagon Antagonists/Inverse Agonists
    Publication number: 20090143592
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Application
    Filed: December 3, 2007
    Publication date: June 4, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Thoger Christensen, Behrend Frederik Lundt, Ulla Grove Sidelmann, Henning Thogersen, Anthony L. Ling, Michael Bruno Plewe, Larry Kenneth Truesdale, Anker Steen Jogensen, Janos Tibor Kodra, Shenghua Shi
  • Compounds and compositions for treating obesity
    Publication number: 20070185128
    Abstract: Described herein are novel and useful compounds of the general formula Compounds of this invention can advantageously exhibit melanocortin receptor agonist activity. New and useful compounds comprising such a chemical structure and methods of modulating melanocortin receptor activity in a subject (and promoting, inducing, and/or enhancing the treatment or prevention of related diseases) by administering such a compound or composition also are described.
    Type: Application
    Filed: November 21, 2003
    Publication date: August 9, 2007
    Inventors: Kilian Conde-Frieboes, Michael Ankersen, Ulrich Sensfuss, Birgitte Wulff, Henning Thogersen, Philipp Lustenberger, Klaus Rudolf, Bernd Krist, Stephan Muller, Dirk Stenkamp, Marcus Schindler, Heike Wieland, Kirsten Arndt
  • Regulation of meiosis
    Publication number: 20050222098
    Abstract: Compounds of Formula I and methods of regulating the meiosis in a mammalian germ cell which method comprises administering an effective amount of the compound of Formula I to a germ cell in need of such a treatment.
    Type: Application
    Filed: May 18, 2005
    Publication date: October 6, 2005
    Applicant: Novo Nordisk A/S
    Inventors: Anne Byskov, Claus Andersen, Lars Nordholm, Henning Thogersen, Ole Wassman, Ivan Diers, Erling Guddal
  • Glucagon antagonists/inverse agonists
    Publication number: 20050203108
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Application
    Filed: November 3, 2004
    Publication date: September 15, 2005
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Christensen, Behrend Lundt, Ulla Sidelmann, Henning Thogersen, Anthony Ling, Michael Plewe, Larry Truesdale, Anker Jogensen, Janos Kodra, Shenghua Shi
  • Glucagon antagonists/inverse agonists
    Publication number: 20030220350
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Application
    Filed: August 30, 2002
    Publication date: November 27, 2003
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Thoger Christensen, Behrend Frederik Lundt, Ulla Grove Sidelmann, Henning Thogersen, Anthony L. Ling, Michael Bruno Plewe, Larry Kenneth Truesdale, Anker Steen Jogensen, Janos Tibor Kodra, Shenghua Shi
  • Regulation of meiosis
    Publication number: 20030004148
    Abstract: Compounds of Formula I and methods of regulating the meiosis in a mammalian germ cell which method comprises administering an effective amount of the compound of Formula I to a germ cell in need of such a treatment.
    Type: Application
    Filed: January 23, 2002
    Publication date: January 2, 2003
    Inventors: Anne G. Byskov, Claus Y. Andersen, Lars Nordholm, Henning Thogersen, Ole Wassman, Ivan Verner Diers, Erling Guddahl
  • Compounds with growth hormone releasing properties
    Patent number: 5990084
    Abstract: The present invention related to truncated GHRs of the general formula IK-(M).sub.x -A-B-(C).sub.w -D-E-(F).sub.z -G-(N).sub.y -L (I)which have the ability to stimulate release of endogenous growth hormone.
    Type: Grant
    Filed: April 18, 1997
    Date of Patent: November 23, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Stefan Lutz Richter, Kjeld Madsen, Henning Thogersen, Nils Langeland Johansen, Ole Hvilsted Olsen, Peter Hongaard Andersen, Annette Hansen
  • N-substituted naphthofused lactams
    Patent number: 5817654
    Abstract: The present invention relates to novel N-substituted naphthofused lactams and salts thereof of the formula ##STR1## Compounds of the general formula I possess the ability to stimulate the release of endogenous growth hormone. Thus, these compounds may be used in the treatment of conditions which require stimulation of growth hormone production or secretion such as in humans with growth hormone deficiency or where increased growth hormone plasma levels are desired, for instance in elderly patients or in livestock.
    Type: Grant
    Filed: January 29, 1997
    Date of Patent: October 6, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Henning Thogersen, Birgit Sehested Hansen, Bernd Peschke, Thomas Kruse Hansen, Knud Erik Andersen